Carregant...
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing t...
Guardat en:
| Publicat a: | Diabetes Ther |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6965597/ https://ncbi.nlm.nih.gov/pubmed/31813092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00728-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|